Literature DB >> 12734225

Candida dubliniensis at a university hospital in Saudi Arabia.

R Fotedar1, S S A Al-Hedaithy.   

Abstract

Candida dubliniensis is a newly described yeast species that is a close phylogenetic relative of C. albicans. Although it has been reported from different parts of the world, no detailed investigation of this species has been done in Saudi Arabia. The purpose of the present study was to identify C. dubliniensis isolates recovered from clinical specimens at a tertiary-care hospital in Riyadh, Saudi Arabia, and to determine the drug susceptibility profiles of those isolates. Over a period of 8 months, 823 germ tube- and chlamydospore-positive yeasts identified as C. albicans and recovered from different clinical specimens were screened for their ability to grow at 45 degrees C on Sabouraud dextrose agar. Isolates which failed to grow at 45 degrees C were presumptively identified as C. dubliniensis. The species identities were further confirmed by the production of pseudohyphae and chlamydospores on Staib agar and their inability to assimilate D-xylose and alpha-methyl-D-glucoside by using the API 20C AUX system. A total of 27 (3.3%) isolates were identified as C. dubliniensis. They were all recovered from 23 human immunodeficiency virus-negative patients. The prevalence of C. dublinensis in bronchoalveolar lavage (33.3%), oral (16.7%), and blood (16.7%) specimens was high. In addition, 33 isolates previously identified as C. albicans and preserved among our stock blood culture isolates were also recruited for the study. Of these, 5 isolates were found to be C. dubliniensis, thus making the total number of isolates identified as this species 32. Antifungal susceptibility testing of the C. dubliniensis isolates showed 100% sensitivity to amphotericin B, 97% sensitivity to each of fluconazole and ketoconazole, and 87.5% sensitivity to itraconazole. However, in contrast to other studies, the majority of the isolates (65.6%) showed high levels of resistance to flucytosine (MIC > 64 microg/ml). Further studies are warranted to investigate the cause of this unusually high rate of resistance to flucytosine of the C. dubliniensis isolates in this region.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734225      PMCID: PMC154754          DOI: 10.1128/JCM.41.5.1907-1911.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Candida dubliniensis at a cancer center.

Authors:  A Sebti; T E Kiehn; D Perlin; V Chaturvedi; M Wong; A Doney; S Park; K A Sepkowitz
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

2.  One-year prevalence of Candida dublinienis in a Dutch university hospital.

Authors:  J F Meis; F M Lunel; P E Verweij; A Voss
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

3.  Retrospective identification and characterization of Candida dubliniensis isolates among Candida albicans clinical laboratory isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected individuals.

Authors:  M A Jabra-Rizk; W A Falkler; W G Merz; A A Baqui; J I Kelley; T F Meiller
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

4.  Recovery of Candida dubliniensis from non-human immunodeficiency virus-infected patients in Israel.

Authors:  I Polacheck; J Strahilevitz; D Sullivan; S Donnelly; I F Salkin; D C Coleman
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

5.  In vitro susceptibility of Candida dubliniensis to current and new antifungal agents.

Authors:  G Quindós; A J Carrillo-Muñoz; M P Arévalo; J Salgado; R Alonso-Vargas; J M Rodrigo; M T Ruesga; A Valverde; J Pemán; E Cantón; E Martín-Mazuelos; J Pontón
Journal:  Chemotherapy       Date:  2000 Nov-Dec       Impact factor: 2.544

6.  Differentiation of Candida dubliniensis from Candida albicans on staib agar and caffeic acid-ferric citrate agar.

Authors:  A Al Mosaid; D Sullivan; I F Salkin; D Shanley; D C Coleman
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

7.  Flucytosine primary resistance in Candida species and Cryptococcus neoformans.

Authors:  M Cuenca-Estrella; T M Díaz-Guerra; E Mellado; J L Rodríguez-Tudela
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-04       Impact factor: 3.267

8.  Identification of Candida dubliniensis based on temperature and utilization of xylose and alpha-methyl-D-glucoside as determined with the API 20C AUX and vitek YBC systems.

Authors:  A C Gales; M A Pfaller; A K Houston; S Joly; D J Sullivan; D C Coleman; D R Soll
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

9.  Rapid identification of Candida dubliniensis with commercial yeast identification systems.

Authors:  D H Pincus; D C Coleman; W R Pruitt; A A Padhye; I F Salkin; M Geimer; A Bassel; D J Sullivan; M Clarke; V Hearn
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

10.  Candida dubliniensis fungemia: the first four cases in North America.

Authors:  M E Brandt; L H Harrison; M Pass; A N Sofair; S Huie; R K Li; C J Morrison; D W Warnock; R A Hajjeh
Journal:  Emerg Infect Dis       Date:  2000 Jan-Feb       Impact factor: 6.883

View more
  10 in total

1.  Candida dubliniensis screening using the germ tube test in clinical yeast isolates and prevalence of C. dubliniensis in Korea.

Authors:  Tae-Hyoung Kim; Bo-Rae G Park; Hye Ryoun Kim; Mi-Kyung Lee
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

2.  Novel 5-flucytosine-resistant clade of Candida dubliniensis from Saudi Arabia and Egypt identified by Cd25 fingerprinting.

Authors:  Asmaa Al Mosaid; Derek J Sullivan; Itzhack Polacheck; Faisal A Shaheen; Osama Soliman; Saleh Al Hedaithy; Sahar Al Thawad; Motaz Kabadaya; David C Coleman
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  First isolation of Candida dubliniensis from oral cavities of dermatological patients in Nanjing, China.

Authors:  Yi P Ge; Guo X He; Tong Lin; Gui X Lu; Yong N Shen; Wei D Liu
Journal:  Mycopathologia       Date:  2011-07-17       Impact factor: 2.574

4.  Discrimination between Candida albicans and Candida dubliniensis isolated from HIV-positive patients by using commercial method in comparison with PCR assay.

Authors:  H Bujdáková; S Melkusová; I Soji; M Mokrás; Y Mikami
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

Review 5.  Candida dubliniensis: epidemiology and phenotypic methods for identification.

Authors:  Erico Silva Loreto; Liliane A Scheid; Cristina W Nogueira; Gilson Zeni; Janio M Santurio; Sydney H Alves
Journal:  Mycopathologia       Date:  2010-02-21       Impact factor: 2.574

6.  Tobacco agar, a new medium for differentiating Candida dubliniensis from Candida albicans.

Authors:  Zia U Khan; Suhail Ahmad; Eiman Mokaddas; Rachel Chandy
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

7.  Hypertonic sabouraud dextrose agar as a substrate for differentiation of Candida dubliniensis.

Authors:  Oncü Akgül; Nilgün Cerikçioğlu
Journal:  Mycopathologia       Date:  2009-02-20       Impact factor: 2.574

8.  Genetic relatedness of subgingival and buccal Candida dubliniensis isolates in immunocompetent subjects assessed by RAPD-PCR.

Authors:  Virginia Marta Jewtuchowicz; Maria Teresa Mujica; Maria Celina Malzone; Alicia Cuesta; Maria Lorena Nastri; Cristina Adela Iovannitti; Alcira Cristina Rosa
Journal:  J Oral Microbiol       Date:  2009-10-15       Impact factor: 5.474

9.  Candida dubliniensis: an appraisal of its clinical significance as a bloodstream pathogen.

Authors:  Ziauddin Khan; Suhail Ahmad; Leena Joseph; Rachel Chandy
Journal:  PLoS One       Date:  2012-03-02       Impact factor: 3.240

10.  One year prospective survey of Candida bloodstream infections in Scotland.

Authors:  Frank C Odds; Mary F Hanson; Amanda D Davidson; Mette D Jacobsen; Pauline Wright; Julie A Whyte; Neil A R Gow; Brian L Jones
Journal:  J Med Microbiol       Date:  2007-08       Impact factor: 2.472

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.